Could CRISPR Technology Rise As A Hero In The Era Of Antibiotic Resistance?

CRISPR has been making waves with its success in fighting rare genetic diseases, but could it also help turn bacterium’s machinery against itself? In the era of superbugs, scientists are hopeful the technology can be a game-changer. Meanwhile, GSK has announced a late-stage study for its new antibiotic to fight urinary tract infections and gonorrhea.

The New York Times: Is Crispr The Next Antibiotic?

For decades, scientists and doctors have treated common bacterial and viral infections with fairly blunt therapies. If you developed a sinus infection or a stomach bug, you would likely be given a broad-spectrum antibiotic that would clear out many different types of bacteria. Antiviral drugs help treat viral illnesses in much the same way, by hindering the pathogen’s ability to reproduce and spread in the body. (Sheikh, 10/28)

Reuters: GlaxoSmithKline Starts Late-Stage Trial For Experimental Antibiotic

GlaxoSmithKline Plc said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infection and gonorrhoea, a type of sexually transmitted infection. The antibiotic, gepotidacin, is the first of a new class of drugs and is expected to treat the two common infections caused by bacteria - identified as antibiotic resistant threats by U.S. health regulators. (10/28)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics